ADIPOR3 Antibody

What is ADIPOR3 and what role does it play in adiponectin signaling?

ADIPOR3 (Adiponectin Receptor 3) belongs to the adiponectin receptor family, which includes the better-characterized AdipoR1 and AdipoR2. Unlike AdipoR1 and AdipoR2, ADIPOR3's specific functions remain less well-defined in the current literature. The receptor has been identified in various species, including Oryza sativa subsp. japonica (Rice), as indicated by antibody reactivity data .

The adiponectin receptor family mediates the biological effects of adiponectin, a hormone primarily secreted by adipose tissue that regulates glucose metabolism and fatty acid oxidation. While AdipoR1 and AdipoR2 have established roles in these processes, ADIPOR3's specific signaling pathways and biological functions require further investigation. Research suggests that unlike ADIPOR1 and ADIPOR2, ADIPOR3 may not function as a primary receptor for CTRP3 (C1q/TNF-related protein 3), as studies have demonstrated that CTRP3 functions through AdipoR2 but not AdipoR1 or AdipoR3 .

What considerations are important when selecting an ADIPOR3 antibody?

When selecting an ADIPOR3 antibody, researchers should consider several critical factors:

• Antibody type: Determine whether a polyclonal or monoclonal antibody better suits your experimental needs. Polyclonal antibodies like the CSB-PA970051XA01OFG recognize multiple epitopes and may provide higher sensitivity, while monoclonal antibodies offer greater specificity for a single epitope .

• Species reactivity: Verify that the antibody recognizes ADIPOR3 in your species of interest. Available antibodies have been validated for species such as Oryza sativa (Rice), but cross-reactivity with mammalian ADIPOR3 should be confirmed before use .

• Applications: Ensure the antibody has been validated for your specific application (Western blot, ELISA, immunohistochemistry, etc.). For example, the CSB-PA970051XA01OFG antibody has been tested for ELISA and Western blot applications .

• Immunogen information: Review the immunogen used to generate the antibody. For example, some ADIPOR3 antibodies are generated using recombinant proteins as immunogens, which affects epitope recognition .

• Validation data: Request validation data demonstrating specificity, such as Western blots showing a single band of the expected molecular weight, or appropriate controls showing absence of signal when the target is not present .

What are the recommended storage and handling conditions for ADIPOR3 antibodies?

Proper storage and handling of ADIPOR3 antibodies are essential to maintain their performance and extend their shelf life:

• Temperature: Store antibodies at -20°C or -80°C for long-term preservation. Avoid repeated freeze-thaw cycles as they can degrade antibody quality and reduce binding efficiency .

• Buffer composition: Most ADIPOR3 antibodies are supplied in buffers containing preservatives and stabilizers. For example, some formulations include 50% glycerol, 0.01M PBS (pH 7.4), and 0.03% Proclin 300 as a preservative . These components help maintain antibody stability during storage.

• Aliquoting: To prevent repeated freeze-thaw cycles, divide antibodies into single-use aliquots upon receipt. This practice is particularly important for polyclonal antibodies, which may be more susceptible to degradation .

• Working dilutions: Prepare working dilutions immediately before use rather than storing diluted antibodies for extended periods, as dilution decreases stability .

• Temperature transitions: When removing antibodies from freezer storage, allow them to thoroughly thaw at cool temperatures (e.g., on ice or in a refrigerator) rather than at room temperature to preserve activity .

How should ADIPOR3 antibody validation be performed to ensure specificity?

Comprehensive validation of ADIPOR3 antibodies requires multiple approaches to confirm specificity:

• Western blot analysis: Run samples containing ADIPOR3 alongside negative controls (e.g., knockout tissues or cell lines) to verify that the antibody detects a single band of the expected molecular weight. Compare the results with a reference antibody if available . For adiponectin receptor antibodies, gradient SDS-PAGE (4-12%) has been successfully used for detection in serum samples .

• Peptide competition assay: Pre-incubate the antibody with the immunizing peptide before application in your experimental system. This should abolish specific binding if the antibody is truly recognizing ADIPOR3 .

• Epitope mapping: Consider epitope mapping technologies such as PEPperMAP® to precisely identify the binding site of your antibody. This approach uses peptide microarrays with overlapping peptides (e.g., 15-amino acid peptides with 14-amino acid overlaps) to determine exactly where your antibody binds .

• Immunoprecipitation followed by mass spectrometry: This technique can confirm that the antibody is pulling down ADIPOR3 specifically, rather than cross-reacting with other proteins .

• Cross-reactivity testing: Test the antibody against homologous proteins (AdipoR1, AdipoR2) to ensure it specifically recognizes ADIPOR3 and does not cross-react with these related receptors .

What are the optimal protocols for detecting ADIPOR3 in different experimental systems?

Optimizing protocols for ADIPOR3 detection requires adaptation to specific experimental systems:

• Western blotting optimization:

  • Use gradient gels (4-12%) for optimal resolution of ADIPOR3

  • Block with 6% non-fat milk in TBST buffer (10 mM Tris-Cl [pH 8.0], 150 mM NaCl, 0.05% Tween 20)

  • Incubate with primary antibody (optimal concentration typically 1-5 μg/mL) at 4°C overnight

  • For visualization, ECL detection systems provide good sensitivity for most applications

• Immunohistochemistry optimization:

  • Tissue fixation and antigen retrieval methods significantly impact staining quality and should be empirically determined for ADIPOR3

  • Initial antibody dilutions of 1:200-1:500 are recommended as starting points for optimization

  • Include positive and negative control tissues in each run to validate staining patterns

  • For visualization, 3,3′-diaminobenzidine (DAB) with hematoxylin counterstaining provides good contrast

• Flow cytometry considerations:

  • Cell permeabilization may be necessary for optimal detection of ADIPOR3, depending on the epitope location

  • Titration of antibody concentration is essential to determine the optimal signal-to-noise ratio

  • Include appropriate isotype controls to assess non-specific binding

How do ADIPOR3 expression patterns compare across different tissues and experimental models?

Understanding ADIPOR3 expression patterns requires systematic analysis across tissues and models:

• Tissue-specific expression:

  • While tissue-specific expression data for ADIPOR3 is limited compared to AdipoR1 and AdipoR2, researchers should consider examining multiple tissues within their experimental model

  • Expression patterns may vary significantly between different physiological and pathological states

  • When studying novel tissues, perform initial screening with qPCR to identify tissues with detectable ADIPOR3 expression before antibody-based studies

• Cross-species considerations:

  • ADIPOR3 sequence homology varies across species, potentially affecting antibody recognition

  • When working with non-validated species, perform Western blot validation before proceeding to more complex applications

  • Consider sequence alignment analysis to predict potential cross-reactivity

• Expression in disease models:

  • Changes in ADIPOR3 expression should be evaluated in the context of related receptors (AdipoR1, AdipoR2)

  • The CTRP3-AdipoR axis has been implicated in autoimmune diseases, suggesting potential roles for adiponectin receptors in immune regulation

  • Consider examining ADIPOR3 expression in different immune cell populations, as adiponectin receptors have demonstrated roles in T cell differentiation

What are the best practices for using ADIPOR3 antibodies in Western blot experiments?

Optimizing Western blot protocols for ADIPOR3 detection requires attention to several critical factors:

• Sample preparation:

  • For cell or tissue lysates, use lysis buffers containing protease inhibitors to prevent ADIPOR3 degradation

  • For membrane proteins like ADIPOR3, consider specialized lysis buffers containing mild detergents that preserve protein structure

  • Heat samples at 70°C rather than boiling to prevent aggregation of membrane proteins

• Gel selection and electrophoresis:

  • Use gradient gels (4-12%) for optimal resolution of ADIPOR3

  • Include positive controls (tissues/cells known to express ADIPOR3) and molecular weight markers

  • For membrane proteins, avoid extended heating of samples which can cause aggregation

• Transfer and blocking:

  • Optimize transfer conditions for membrane proteins (typically lower current for longer time)

  • Block with 6% non-fat milk in TBST buffer (10 mM Tris-Cl [pH 8.0], 150 mM NaCl, 0.05% Tween 20)

  • Consider alternative blocking agents if background is problematic

• Antibody incubation and detection:

  • Determine optimal antibody concentration through titration (typically 1-5 μg/mL for purified antibodies)

  • Incubate with primary antibody at 4°C overnight for best results

  • For visualization, ECL detection provides good sensitivity for most applications

• Quantification:

  • Include loading controls appropriate for your sample type

  • Use digital imaging systems for quantification rather than film for more accurate densitometry

  • Validate linearity of signal across a range of protein concentrations

How can ADIPOR3 antibodies be effectively used in immunohistochemistry and immunofluorescence?

Successful application of ADIPOR3 antibodies in immunohistochemistry (IHC) requires optimization of several parameters:

• Tissue preparation:

  • Fixation method significantly impacts epitope accessibility; compare paraformaldehyde, formalin, and other fixatives

  • Section thickness (typically 4-6 μm) affects antibody penetration and signal intensity

  • Antigen retrieval methods should be empirically tested (heat-induced vs. enzymatic retrieval)

• Blocking and antibody incubation:

  • Block endogenous peroxidase activity before antibody incubation for IHC

  • Test different blocking solutions to minimize background (normal serum matching the secondary antibody species)

  • Initial antibody dilutions of 1:200-1:500 are recommended as starting points

  • Longer incubation times (overnight at 4°C) may improve specific staining while reducing background

• Detection systems:

  • For chromogenic IHC, 3,3′-diaminobenzidine (DAB) with hematoxylin counterstaining provides good contrast

  • For immunofluorescence, select fluorophores with appropriate spectral properties to avoid autofluorescence

  • Amplification systems (tyramide signal amplification) may enhance detection of low-abundance targets

• Controls and validation:

  • Include positive and negative control tissues in each experiment

  • Peptide competition controls confirm specificity of staining

  • For semi-quantitative analysis, use established scoring systems (e.g., 0 = staining in <10% of cells, 1 = staining in 10-50% of cells, 2 = staining in >50% of cells)

What approaches can be used to study the interaction between ADIPOR3 and potential ligands?

Investigating ADIPOR3-ligand interactions requires specialized techniques:

• Co-immunoprecipitation (Co-IP):

  • Use ADIPOR3 antibodies to immunoprecipitate the receptor complex from cell lysates

  • Analyze co-precipitated proteins by Western blot or mass spectrometry to identify interacting partners

  • Crosslinking before lysis may stabilize transient interactions

  • Controls should include immunoprecipitation with isotype-matched control antibodies

• Proximity ligation assay (PLA):

  • This technique can visualize protein-protein interactions in situ

  • Requires antibodies against both ADIPOR3 and its potential ligand from different species

  • Provides spatial information about where interactions occur within cells or tissues

  • Quantification of PLA signals can estimate relative interaction strengths

• Functional assays:

  • Similar to studies with AdipoR2, use receptor antagonists to block potential ADIPOR3-ligand interactions

  • Assess downstream signaling events (e.g., AMPK activation, PPAR signaling) after ligand stimulation with and without antagonists

  • Measure changes in gene expression of potential target genes (e.g., using methods similar to those that identified Rorc and Stat3 regulation by AdipoR2)

• Binding assays:

  • Use purified proteins for direct binding assays (surface plasmon resonance, isothermal titration calorimetry)

  • For cell-based assays, compare binding to cells expressing ADIPOR3 versus control cells

  • Competition assays with known ligands can reveal binding site similarities or differences

What are common issues when working with ADIPOR3 antibodies and how can they be resolved?

Researchers frequently encounter several challenges when working with ADIPOR3 antibodies:

• Non-specific binding:

  • Problem: Multiple bands in Western blot or diffuse staining in IHC

  • Solution: Increase blocking time/concentration, test different blocking agents, optimize antibody concentration, perform peptide competition assays to confirm specificity

• Weak or no signal:

  • Problem: Insufficient detection of ADIPOR3 despite known expression

  • Solution: Optimize antigen retrieval for IHC, increase antibody concentration or incubation time, check storage conditions of antibody, verify target expression using qPCR

• Inconsistent results between experiments:

  • Problem: Variable staining patterns or band intensities

  • Solution: Standardize protocols, prepare fresh working dilutions for each experiment, aliquot antibodies to avoid freeze-thaw cycles, include positive controls in each experiment

• Cross-reactivity with other adiponectin receptors:

  • Problem: Difficulty distinguishing between ADIPOR3 and related receptors (AdipoR1, AdipoR2)

  • Solution: Validate antibody specificity using cells/tissues with differential expression of receptor subtypes, perform siRNA knockdown experiments, use receptor antagonists to confirm specificity

• Batch-to-batch variability:

  • Problem: Different performance between antibody lots

  • Solution: Request data demonstrating lot consistency from suppliers, purchase larger quantities of a single lot for long-term projects, validate each new lot against previous standards

How can researchers interpret conflicting results between different detection methods for ADIPOR3?

When faced with discrepancies between different detection methods:

• Understand methodological differences:

  • Different techniques detect different aspects of ADIPOR3 biology (protein levels, localization, functional state)

  • Western blot detects denatured protein, while IHC and IF can show native conformation and localization

  • Flow cytometry typically measures surface expression, which may differ from total cellular levels

• Systematic validation approach:

  • Confirm antibody specificity in each method independently using appropriate controls

  • Use multiple antibodies targeting different epitopes of ADIPOR3 to corroborate findings

  • Complement antibody-based detection with non-antibody methods (qPCR, mass spectrometry)

• Consider biological variables:

  • Post-translational modifications may affect epitope recognition in different assays

  • Receptor internalization or trafficking may explain differences between surface and total expression

  • Tissue-specific expression patterns might influence antibody accessibility or background

• Quantitative considerations:

  • Establish appropriate quantification methods for each technique

  • For IHC, use standardized scoring systems (0-2 scale based on percentage of positive cells)

  • For Western blot, normalize to appropriate loading controls and validate linearity of signal

What experimental controls are essential when studying ADIPOR3 expression and function?

Rigorous experimental design requires comprehensive controls:

• Antibody specificity controls:

  • Peptide competition/blocking experiments to confirm binding specificity

  • Use of tissues/cells known to be negative for ADIPOR3 expression

  • Isotype-matched control antibodies to assess non-specific binding

• Technical controls:

  • For Western blot: molecular weight markers, positive control samples

  • For IHC/IF: positive and negative control tissues in each staining run

  • For functional assays: specific receptor antagonists (similar to AdipoR1/R2 blockers used in T cell differentiation studies)

• Biological validation:

  • siRNA or CRISPR-mediated knockdown of ADIPOR3 to confirm antibody specificity

  • Overexpression systems to verify antibody detection capability

  • Parallel analysis of related receptors (AdipoR1, AdipoR2) to assess relative expression or function

• Quantification controls:

  • Standard curves for absolute quantification

  • Appropriate housekeeping genes or proteins as loading/normalization controls

  • Technical replicates to assess method reproducibility and biological replicates to account for natural variation

How might advances in antibody technology improve ADIPOR3 research?

Emerging antibody technologies offer promising opportunities for ADIPOR3 research:

• Single-domain antibodies and nanobodies:

  • Smaller size allows better tissue penetration and access to concealed epitopes

  • Greater stability under varying conditions

  • Potential for improved specificity for distinguishing between closely related adiponectin receptors

• Recombinant antibody engineering:

  • Creation of bispecific antibodies targeting ADIPOR3 and potential interaction partners

  • Development of antibodies with modified Fc regions for specific applications

  • Humanized antibodies for potential therapeutic applications

• Advanced imaging applications:

  • Development of directly labeled ADIPOR3 antibodies for live-cell imaging

  • Super-resolution microscopy compatible antibody conjugates

  • Antibodies optimized for tissue clearing techniques and 3D imaging

• Functional antibodies:

  • Development of antibodies that can modulate ADIPOR3 activity (agonistic or antagonistic)

  • Similar to approaches studying AdipoR2 in T cell differentiation, functional antibodies could help elucidate ADIPOR3's role in various physiological processes

What is the potential role of ADIPOR3 in disease processes and therapeutic development?

Understanding ADIPOR3's role in disease could open new therapeutic avenues:

• Autoimmune and inflammatory conditions:

  • Research on adiponectin receptors has revealed roles in T cell differentiation and autoimmune diseases like experimental autoimmune encephalomyelitis

  • ADIPOR3's function in these processes requires further investigation, building on knowledge of the CTRP3-AdipoR2 axis

• Metabolic disorders:

  • Given the established roles of AdipoR1 and AdipoR2 in metabolic regulation, ADIPOR3 might have complementary or regulatory functions

  • Specific antibodies could help map ADIPOR3 expression in metabolic tissues and identify dysregulation in disease states

• Therapeutic antibody development:

  • Understanding of epitope mapping techniques, as applied to adiponectin receptor antibodies, provides a foundation for developing therapeutic antibodies targeting ADIPOR3

  • Potential for developing antibodies that can modulate ADIPOR3 activity to treat specific conditions

• Diagnostic applications:

  • ADIPOR3 expression changes might serve as biomarkers for disease states

  • Antibody-based detection methods would be crucial for such diagnostic applications

How can multi-omics approaches complement antibody-based studies of ADIPOR3?

Integrating multiple omics technologies with antibody studies provides comprehensive insights:

• Transcriptomics-proteomics integration:

  • Correlate ADIPOR3 mRNA levels with protein expression across tissues and conditions

  • Identify post-transcriptional regulation mechanisms affecting ADIPOR3 expression

  • Similar to approaches used for studying adiponectin receptor expression in autoimmune models

• Interactomics:

  • Combine immunoprecipitation with mass spectrometry to identify ADIPOR3 interaction partners

  • Map interaction networks to understand ADIPOR3's role in cellular signaling pathways

  • Validate key interactions with targeted antibody-based approaches

• Single-cell approaches:

  • Use antibodies for single-cell protein profiling in combination with transcriptomics

  • Identify cell populations with unique ADIPOR3 expression patterns

  • Relate receptor expression to functional cellular states

• Structural biology integration:

  • Use antibody epitope mapping data to inform structural studies of ADIPOR3

  • Apply structural information to improve antibody design and specificity

  • Develop structure-function relationships to understand ADIPOR3 signaling mechanisms